CoChat

Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer

Open access
Pettazzoni, Piergiorgio, Viale, Andrea, Shah, Parantu, Carugo, Alessandro, Ying, Haoqiang, Wang, Huamin, Genovese, Giannicola, Seth, Sahil, Minelli, Rosalba, Green, Tessa, Huang-Hobbs, Emmet, Corti, Denise, Sanchez, Nora, Nezi, Luigi, Marchesini, Matteo, Kapoor, Avnish, Yao, Wantong, Francesco, Maria E. Di, Petrocchi, Alessia, Deem, Angela K., Scott, Kenneth, Colla, Simona, Mills, Gordon B., Fleming, Jason B., Heffernan, Timothy P., Jones, Philip, Toniatti, Carlo, DePinho, Ronald A., Draetta, Giulio F. · 2015 · Cancer Research
Cited by 81

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Mutated KRAS (KRAS*) is a fundamental driver in the majority of pancreatic ductal adenocarcinomas (PDAC). Using an inducible mouse model of KRAS*-driven PDAC, we compared KRAS* genetic extinction with pharmacologic inhibition of MEK1 in tumor spheres and in vivo. KRAS* ablation blocked proliferation and induced apoptosis, whereas MEK1 inhibition exerted cytostatic effects. Proteomic analysis evidenced that MEK1 inhibition was accompanied by a sustained activation of the PI3K–AKT–MTOR pathway and by the activation of AXL, PDGFRa, and HER1–2 receptor tyrosine kinases (RTK) expressed in a large proportion of human PDAC samples analyzed. Although single inhibition of each RTK alone or plus MEK1 inhibitors was ineffective, a combination of inhibitors targeting all three coactivated RTKs and MEK1 was needed to inhibit proliferation and induce apoptosis in both mouse and human low-passage PDAC cultures. Importantly, constitutive AKT activation, which may mimic the fraction of AKT2-amplified PDAC, was able to bypass the induction of apoptosis caused by KRAS* ablation, highlighting a potential inherent resistance mechanism that may inform the clinical application of MEK inhibitor therapy. This study suggests that combinatorial-targeted therapies for pancreatic cancer must be informed by the activation state of each putative driver in a given treatment context. In addition, our work may offer explanative and predictive power in understanding why inhibitors of EGFR signaling fail in PDAC treatment and how drug resistance mechanisms may arise in strategies to directly target KRAS. Cancer Res; 75(6); 1091–101. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-14-1854

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 81

Metadata

Authors
Pettazzoni, P., Viale, A., Shah, P., Carugo, A., Ying, H., Wang, H., Genovese, G., Seth, S., Minelli, R., Green, T., Huang-Hobbs, E., Corti, D., Sanchez, N., Nezi, L., Marchesini, M., Kapoor, A., Yao, W., Francesco, M. E. D., Petrocchi, A., Deem, A. K., Scott, K., Colla, S., Mills, G. B., Fleming, J. B., Heffernan, T. P., Jones, P., Toniatti, C., DePinho, R. A., & Draetta, G. F.
Venue
Cancer Research
Published
2015-03-12
Volume
75
Issue
6
Pages
1091-1101
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2128086717
Cited by
81
References
18
FWCI
3.90
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-14-1854
The paper
Pettazzoni, P., Viale, A., Shah, P., Carugo, A., Ying, H., Wang, H., Genovese, G., Seth, S., Minelli, R., Green, T., Huang-Hobbs, E., Corti, D., Sanchez, N., Nezi, L., Marchesini, M., Kapoor, A., Yao, W., Francesco, M. E. D., Petrocchi, A., . . . Draetta, G. F. (2015). Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-14-1854

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.